Provectus Announces First Peer-Reviewed Publication on PV-10 in Melanoma Research

Provectus Announces First Peer-Reviewed Publication on PV-10 in "Melanoma Research"KNOXVILLE, Tenn.TN-PROVECTUS-PHARMA KNOXVILLE, Tenn.--(BUSINESS WIRE)-- Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced that 'Melanoma Research' has published a paper entitled, 'Chemoablation of metastatic melanoma using intralesional Rose Bengal,' on its website. The paper is authored by Professor John F. Thompson, M.D. and his colleagues, Professor Peter Hersey, M.D. and Eric Wachter, Ph.D. The paper details results of Provectus' Phase 1 clinical trial of PV-10, and is scheduled for print publication in the December issue of the journal. The paper presents clinical data for the first 11 subjects in the Phase 1 trial. In this initial cohort, up to three target... [read full story]